Ken Griffin
XERS icon

Ken Griffin’s Xeris Biopharma Holdings XERS Stock Holding History

Ken Griffin’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318K Buy
54,900
+34,000
+163% +$225K ﹤0.01% 10340
2025
Q4 		$164K Sell
20,900
-26,200
-56% -$206K ﹤0.01% 11213
2025
Q3 		$383K Buy
47,100
+800
+2% +$5.32K ﹤0.01% 9769
2025
Q2 		$216K Sell
46,300
-9,500
-17% -$43.5K ﹤0.01% 10512
2025
Q1 		$306K Buy
55,800
+34,100
+157% +$138K ﹤0.01% 9534
2024
Q4 		$73.6K Sell
21,700
-24,000
-53% -$77.2K ﹤0.01% 11900
2024
Q3 		$130K Buy
45,700
+700
+2% +$1.8K ﹤0.01% 10753
2024
Q2 		$101K Sell
45,000
-35,400
-44% -$71.3K ﹤0.01% 10905
2024
Q1 		$178K Buy
80,400
+16,600
+26% +$42.9K ﹤0.01% 10515
2023
Q4 		$150K Buy
63,800
+23,500
+58% +$43.4K ﹤0.01% 10385
2023
Q3 		$75K Sell
40,300
-10,400
-21% -$23.8K ﹤0.01% 11247
2023
Q2 		$133K Buy
50,700
+18,900
+59% +$48.1K ﹤0.01% 10511
2023
Q1 		$51.8K Sell
31,800
-32,600
-51% -$40.8K ﹤0.01% 12099
2022
Q4 		$85.7K Buy
64,400
+20,800
+48% +$29.4K ﹤0.01% 11432
2022
Q3 		$68K Sell
43,600
-2,700
-6% -$4.46K ﹤0.01% 11412
2022
Q2 		$71K Buy
46,300
+400
+0.9% +$844 ﹤0.01% 11695
2022
Q1 		$118K Sell
45,900
-163,100
-78% -$398K ﹤0.01% 12101
2021
Q4 		$612K Buy
209,000
+15,400
+8% +$33.3K ﹤0.01% 9185
2021
Q3 		$474K Sell
193,600
-19,700
-9% -$57.2K ﹤0.01% 10000
2021
Q2 		$868K Sell
213,300
-1,400
-0.7% -$5.34K ﹤0.01% 8720
2021
Q1 		$968K Sell
214,700
-76,800
-26% -$414K ﹤0.01% 8199
2020
Q4 		$1.43M Buy
291,500
+255,000
+699% +$1.28M ﹤0.01% 6035
2020
Q3 		$216K Sell
36,500
-21,000
-37% -$84K ﹤0.01% 8688
2020
Q2 		$153K Buy
57,500
+46,200
+409% +$161K ﹤0.01% 8733
2020
Q1 		$22K Buy
+11,300
New +$48.6K ﹤0.01% 9279

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ken Griffin's XERS Position: Q1 2026 in Review

Ken Griffin increased its Xeris Biopharma Holdings (XERS) stake by 66% in Q1 2026, buying an estimated $1.8M and bringing the position to 681,634 shares worth $3.95M. The position accounts for ﹤0.01% of the portfolio, ranked #4732.

Ken Griffin first reported a position in XERS in Q2 2018 and has held it in 21 quarters since. The position peaked at $7.4M in Q1 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Ken Griffin held 681,634 shares of Xeris Biopharma Holdings worth $3.95M as of Q1 2026.
  • Ken Griffin bought 271,814 Xeris Biopharma Holdings shares in Q1 2026, an estimated $1.8M.
  • Xeris Biopharma Holdings made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4732 holding.
  • Ken Griffin first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 21 quarters since.
  • Ken Griffin's Xeris Biopharma Holdings position peaked at $7.4M in Q1 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.